Ad­vo­cates pe­ti­tion FDA to make abor­tion pill ac­ces­si­ble to mis­car­riage pa­tients

As abor­tion bans take ef­fect na­tion­wide, doc­tors and ad­vo­cates have pe­ti­tioned the FDA over con­cerns that the Supreme Court’s Dobbs de­ci­sion leaves a drug used off-la­bel for mis­car­riage treat­ment vul­ner­a­ble to re­stric­tions.

The Amer­i­can Col­lege of Ob­ste­tri­cians and Gy­ne­col­o­gists and 48 oth­er or­ga­ni­za­tions — from the Amer­i­can Civ­il Lib­er­ties Union to the Amer­i­can Med­ical As­so­ci­a­tion to the Planned Par­ent­hood Fed­er­a­tion of Amer­i­ca — re­quest­ed on Tues­day that reg­u­la­tors en­cour­age Dan­co Lab­o­ra­to­ries to file an ap­pli­ca­tion for its preg­nan­cy ter­mi­na­tion pill Mifeprex in mis­car­riage man­age­ment, and al­ter the drug’s Risk Eval­u­a­tion and Mit­i­ga­tion Strat­e­gy so it isn’t “un­du­ly bur­den­some” for that use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER